Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression

BACKGROUND: Sorafenib is a first-line treatment option for advanced hepatocellular carcinoma (HCC) patients; however, survival predictors upon progression have not been well characterized. In the present study, we aimed to show the efficacy of multidisciplinary therapy for patients who had failed to...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Gastroenterol Res Pract
Main Authors: Kondo, Masaaki, Numata, Kazushi, Hara, Koji, Nozaki, Akito, Fukuda, Hiroyuki, Chuma, Makoto, Maeda, Shin, Tanaka, Katsuaki
Formato: Artigo
Idioma:Inglês
Publicado: Hindawi 2017
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5498900/
https://ncbi.nlm.nih.gov/pubmed/28717362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/5728946
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares